Dispersible tablet of cefuroxime axetil

Abstract

The invention provides a dispersible tablet of cefuroxime axetil, wherein the preparation formula includes cefuroxime axetil, loading agents, flow aid, disintegrating agents, surface-active agents, flavoring agents, lubricant, essence, and coating powder. According to the invention, specific disintegrating agents are adopted, meanwhile, the use amount of the disintegrating agents is not increased, the dispersion time of the dispersible tablet is shortened, and the dissolution rate of the dispersible tablet is improved; and meanwhile, flavoring agents and essence are added in the formula to mask bitter of the dispersible tablet of cefuroxime axetil, so that the mouth feel of a patient taking the dispersible tablet of cefuroxime axetil can be improved.

Description

Technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to a pharmaceutical preparation of cefuroxime axetil, in particular to a dispersible tablet of cefuroxime axetil. Background technique [0002] Cefuroxime axetil is a semi-synthetic second-generation cephalosporin with a broad antibacterial spectrum and strong antibacterial activity against Gram-positive and Gram-negative bacteria. It is a prodrug of cefuroxime. After oral administration, it is rapidly hydrolyzed by non-specific esterase in the mucosal cells of the gastrointestinal tract to release cefuroxime and exert its efficacy. Cefuroxime axetil is a lipophilic drug with bitter taste, poor water solubility, difficult to absorb, low bioavailability, and dissolution rate is the limiting factor for drug absorption. [0003] A Chinese patent application document with publication number CN101874791.A discloses a technical solution for improving the dissolution of cefurox...

AI Technical Summary

Problems solved by technology

This technology uses a lot of disintegrants and surfactants, and the production cost is high. At the same time, the risk of discoloration of raw materials and increase of related substances is prone to occur during the wet granulation process.

The publication number is CN101606914A Chinese patent application document discloses a preparation of cefuroxime axetil tablet suitable for direct powder compression, the preparation mainly achieves the powder direct compression effect of the preparation by increasing the fluidity of the auxiliary material, but The required excipients have a large bulk density and good fluidity, among which the bulk density of the disintegrant is greater than 0.35g / cm 3 , the bulk density of the filler is greater than 0.38g / cm 3 , the requirements for excipients are too high, which increases the cost of excipients. At the same time, this product needs to be dispersed within 10 minutes, which fails to meet the requirements of dispersible tablets

Publication number is that CN101703448A Chinese patent application document discloses a kind of direct compression process of cefuroxime axetil dispersible tablet, the proportion of crude drug cefuroxime axetil in the whole tablet is about 30% in this process prescription, increased The amount of auxiliary materials has increased the production cost, and no flavoring agent has been added at the same time, so the taste is poor

Patent WO9944614 discloses that in order to inhibit the gelation of cefuroxime axetil, the weight ratio of amorphous cefuroxime axetil to colloidal silicon dioxide must exceed 1:0.1. According to this prescription, the bulk density of the powder in production It will be relatively low, and the number of compactions in dry granulation will be relatively high, which will increase production costs

Images